Though no TKI is currently approved for the treatment of indolent SM (ISM), the most common variant of SM, several show great potential.
Systemic mastocytosis is a disease with 5 different subtypes. Treating them remains a challenge for physicians today.
Pregnancy is a risk for clinical deterioration in systemic mastocytosis; conversely, systemic mastocytosis poses a risk to the fetus as well.
Given the complexity of systemic mastocytosis, the disease is best managed in a multidisciplinary setting.